173 related articles for article (PubMed ID: 33866591)
1. Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage.
Cascone AE; Daley MJ; Pan N; Padilla-Tolentino E; Milling TJ
Pharmacotherapy; 2021 Jun; 41(6):501-507. PubMed ID: 33866591
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose prothrombin complex concentrate for emergent warfarin reversal among patients with intracranial hemorrhage.
Dietrich SK; Mixon MA; Rech MA
Am J Emerg Med; 2021 Nov; 49():326-330. PubMed ID: 34224954
[TBL] [Abstract][Full Text] [Related]
3. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
5. High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage.
Davis SD; Chauv S; Hickman AW; Collingridge DS; Kjerengtroen S; Fontaine GV
Thromb Res; 2021 Dec; 208():112-116. PubMed ID: 34749042
[TBL] [Abstract][Full Text] [Related]
6. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
8. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
[TBL] [Abstract][Full Text] [Related]
9. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
[TBL] [Abstract][Full Text] [Related]
10. Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin reversal.
Dietrich SK; Mixon M; Holowatyj M; Werth JC; Delgado SA; Mascolo NE; Meister ER; Zoucha SM; Trujillo TC
Am J Emerg Med; 2020 Oct; 38(10):2096-2100. PubMed ID: 33152586
[TBL] [Abstract][Full Text] [Related]
11. Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.
Dybdahl D; Walliser G; Chance Spalding M; Pershing M; Kincaid M
Am J Emerg Med; 2019 Oct; 37(10):1907-1911. PubMed ID: 30651183
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding.
Korobey MJ; Sadaka F; Javed M; Moynihan M; Alsaei A
Neurocrit Care; 2021 Feb; 34(1):112-120. PubMed ID: 32430804
[TBL] [Abstract][Full Text] [Related]
13. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
14. Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate.
Peksa GD; Mokszycki RK; Rech MA; Maynard B; Panos NG; Sweis RT; DeMott JM
Thromb Haemost; 2020 Feb; 120(2):207-215. PubMed ID: 31837652
[TBL] [Abstract][Full Text] [Related]
15. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Panos NG; Cook AM; John S; Jones GM;
Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal.
Brett S; Taylor M; Pamela M; Michael G
Clin Appl Thromb Hemost; 2024; 30():10760296241243368. PubMed ID: 38710155
[No Abstract] [Full Text] [Related]
17. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
18. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
19. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
20. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
